iSpecimen (ISPC)
NASDAQ:ISPC
Top Page
iSpecimen
(NASDAQ:ISPC)
Select Model
Select Model
Rating:41Neutral
Price Target:
$0.36
▲(15.81% Upside)
Action:DowngradedDate:01/28/26
The score is weighed down primarily by weak financial performance (sharp TTM revenue decline, margin deterioration, ongoing losses, and persistent cash burn). Technicals add a mixed-to-weak backdrop (below key longer-term moving averages with negative MACD). Corporate events and valuation provide limited offset given Nasdaq bid-price compliance risk and a negative P/E tied to ongoing losses.
Positive Factors
Platform and Network
iSpecimen’s technology-driven marketplace and broad provider partnerships create durable sourcing advantages for rare and diverse biospecimens. Network effects and institutional relationships support recurring demand from pharma and academia, improving long-term sample access and customer stickiness.
Negative Factors
Sharp Revenue Decline
A ~43% TTM revenue drop signals weakening customer demand or loss of contracts, eroding scale and operating leverage. Sustained top-line decline undermines ability to cover fixed costs and invest in growth, increasing the risk that recovery will require structural changes or new commercial wins.
Read all positive and negative factors
Positive Factors
Negative Factors
Platform and Network
iSpecimen’s technology-driven marketplace and broad provider partnerships create durable sourcing advantages for rare and diverse biospecimens. Network effects and institutional relationships support recurring demand from pharma and academia, improving long-term sample access and customer stickiness.
Read all positive factors
iSpecimen (ISPC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.52M
Dividend YieldN/A
Average Volume (3M)8.88M
Price to Earnings (P/E)―
Beta (1Y)1.06
Revenue Growth-67.73%
EPS Growth58.35%
CountryUS
Employees24
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)N/A
Shares Outstanding9,771,016
10 Day Avg. Volume698,577
30 Day Avg. Volume8,882,166
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.57
Price to Sales (P/S)0.20
P/FCF Ratio-0.23
Enterprise Value/Market Cap-1.07
Enterprise Value/Revenue-0.48
Enterprise Value/Gross Profit-2.25
Enterprise Value/Ebitda0.17
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
iSpecimen Business Overview & Revenue Model
Company Description
iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology...
How the Company Makes Money
iSpecimen generates revenue primarily through the sale of human biospecimens and associated data to researchers, pharmaceutical companies, and academic institutions. The company's revenue model is built on fees charged for the procurement and deli...
iSpecimen Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
44
Neutral
Cash Flow
12
Very Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.35M | 9.29M | 9.93M | 10.40M | 11.14M | 8.18M |
| Gross Profit | 722.54K | 3.99M | 5.11M | 5.65M | 5.89M | 4.60M |
| EBITDA | -9.47M | -12.73M | -8.80M | -8.80M | -5.86M | -1.74M |
| Net Income | -11.53M | -12.50M | -11.10M | -10.25M | -8.96M | -4.65M |
Balance Sheet | ||||||
| Total Assets | 9.00M | 9.35M | 15.82M | 24.62M | 35.72M | 6.21M |
| Cash, Cash Equivalents and Short-Term Investments | 2.78M | 1.88M | 5.01M | 15.31M | 27.74M | 695.91K |
| Total Debt | 281.44K | 312.17K | 196.24K | 185.85K | 3.42M | 12.77M |
| Total Liabilities | 5.92M | 6.04M | 6.08M | 4.31M | 5.93M | 33.49M |
| Stockholders Equity | 3.07M | 3.31M | 9.74M | 20.31M | 29.79M | -27.28M |
Cash Flow | ||||||
| Free Cash Flow | -6.79M | -8.30M | -10.55M | -9.01M | -11.71M | -1.39M |
| Operating Cash Flow | -6.76M | -8.26M | -5.81M | -5.82M | -10.67M | -288.38K |
| Investing Cash Flow | -1.07M | 1.98M | -7.23M | -3.19M | -1.04M | -1.10M |
| Financing Cash Flow | 8.86M | 5.82M | 70.89K | -3.42M | 38.75M | 2.03M |
iSpecimen Technical Analysis
Negative
0.31
Price Trends
0.29
Negative
0.38
Negative
0.74
Negative
Market Momentum
-0.03
Positive
35.37
Neutral
4.07
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ISPC, the sentiment is Negative. The current price of 0.31 is above the 20-day moving average (MA) of 0.23, above the 50-day MA of 0.29, and below the 200-day MA of 0.74, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 35.37 is Neutral, neither overbought nor oversold. The STOCH value of 4.07 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ISPC.
iSpecimen Risk Analysis
iSpecimen disclosed 72 risk factors in its most recent earnings report. iSpecimen reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
iSpecimen Peers Comparison
UnderperformOutperform
Sector (51)
ISPC
iSpecimen
0.16
-1.02
-86.78%
INBS
Intelligent Bio Solutions
3.35
-12.25
-78.53%
BGLC
BioNexus Gene Lab Corp
2.49
-0.50
-16.72%
BIAF
bioAffinity Technologies, Inc.
3.97
-4.15
-51.11%
iSpecimen Corporate Events
Shareholder Meetings
iSpecimen Reschedules 2025 Annual Meeting Amid Quorum Issues
Negative
Jan 27, 2026
iSpecimen Inc. convened its 2025 Annual Meeting of Stockholders on December 31, 2025, but the meeting was adjourned twice—first on December 31 and again when reconvened on January 23, 2026—because the company failed to achieve a quorum...
Shareholder Meetings
iSpecimen Postpones Annual Meeting Due to Lack Quorum
Neutral
Jan 5, 2026
On December 31, 2025, iSpecimen Inc. convened its 2025 annual meeting of stockholders but adjourned it after failing to achieve a quorum of shareholders needed to conduct business on the proposals previously circulated. The company plans to reconv...
Business Operations and StrategyPrivate Placements and Financing
iSpecimen Completes Private Placement, Engages IR Consulting Firm
Positive
Jan 5, 2026
On December 31, 2025, iSpecimen Inc. completed a private placement of its Series C Convertible Non-Voting Preferred Stock and entered into a Consulting Agreement with IR Agency LLC to provide marketing, advertising, and investor communications ser...
Private Placements and Financing
iSpecimen raises capital via new Series C preferred
Neutral
Jan 2, 2026
On December 30, 2025, iSpecimen Inc. entered into a Securities Purchase Agreement with accredited investors to issue 6,875 shares of newly created Series C Convertible Non-Voting Preferred Stock, each with a stated value of $1,000 and sold at $800...
Delistings and Listing ChangesRegulatory Filings and Compliance
iSpecimen Regains Nasdaq Compliance as of November 2025
Positive
Dec 1, 2025
On November 28, 2025, iSpecimen Inc. received confirmation from the Nasdaq Listing Qualifications Staff that it now meets the continued listing requirements under Nasdaq Listing Rules. Previously, on June 4, 2025, the company was notified of non-c...
Delistings and Listing ChangesRegulatory Filings and Compliance
iSpecimen Faces Nasdaq Delisting Notice for Stock Price
Negative
Nov 21, 2025
On November 19, 2025, iSpecimen Inc. received a notice from Nasdaq indicating that its common stock had fallen below the minimum bid price requirement of $1.00 per share for 30 consecutive business days, putting the company out of compliance with ...
Executive/Board Changes
iSpecimen Appoints Katharyn Field as New CEO
Neutral
Nov 7, 2025
On November 7, 2025, iSpecimen Inc. announced significant leadership changes with the appointment of Ms. Katharyn Field as Chief Executive Officer, Secretary, and Treasurer, succeeding Mr. Robert Bradley Lim who resigned from these roles and the B...
Private Placements and FinancingRegulatory Filings and ComplianceShareholder MeetingsStock Split
iSpecimen Approves Key Proposals in Stockholder Meeting
Positive
Nov 3, 2025
On October 30, 2025, iSpecimen Inc. held a special meeting of stockholders to vote on several key proposals. The company successfully approved a reverse stock split, an increase in authorized shares, and amendments related to private financing tra...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.